Karen Knudsen: Lessons learned while rebuilding the American Cancer Society

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Karen E. Knudsen has spent the past year bringing the American Cancer Society into the 21st century.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher

YOU MAY BE INTERESTED IN

Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.
Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login